Featured Research

from universities, journals, and other organizations

Widespread prescribing of Levothyroxine for borderline thyroid hormone levels

Date:
October 7, 2013
Source:
American Medical Association (AMA)
Summary:
A study of patients in the United Kingdom suggests widespread prescribing of the medication levothyroxine sodium to boost thyroid function among patients with borderline high levels of the thyroid-stimulating hormone thyrotropin (a sign of low thyroid function), raising the possibility of overtreatment.

A study of patients in the United Kingdom suggests widespread prescribing of the medication levothyroxine sodium to boost thyroid function among patients with borderline high levels of the thyroid-stimulating hormone thyrotropin (a sign of low thyroid function), raising the possibility of overtreatment, according to a study published by JAMA Internal Medicine, a JAMA Network publication.

Hypothyroidism (low thyroid function) is one of the most common chronic conditions in Western populations, with levothyroxine prescriptions having increased in the United States, England and Wales, according to the study background.

Researchers note that while thyroid function testing has increased, likely resulting in detection of more cases, an additional factor contributing to more prescriptions of thyroid medication may be the lowering of the thyrotropin threshold at which levothyroxine treatment is started in patients. If the increase in prescriptions is due to a lower threshold for treatment, then treatment may result in less benefit and more harm. Overtreatment is associated with an increased risk of fractures and atrial fibrillation (abnormal heart beat), according to researchers.

Peter N. Taylor, M.Sc., M.R.C.P., of the Cardiff University School of Medicine, United Kingdom, and colleagues examined trends in thyrotropin levels before and after levothyroxine therapy. Researchers used data from the United Kingdom Clinical Practice Research Datalink and identified 52,298 patients who received a levothyroxine prescription between 2001 and 2009.

American Thyroid Association guidelines recommend considering levothyroxine therapy at thyrotropin levels of 10 mIU/L or less when there are clear symptoms of hypothyroidism, positive thyroid autoantibodies or evidence of atherosclerotic cardiovascular disease (hardening of the arteries) or heart failure. Treatment of patients with thyrotropin levels at or below 10 mIU/L without symptoms may cause more harm than good and may represent overtreatment.

The study findings indicate that between 2001 and 2009, the median (midpoint) thyrotropin level at the start of levothyroxine treatment declined from 8.7 to 7.9 mIU/L, with an increase in the odds of having levothyroxine therapy start at a thyrotropin level of 10 mIU/L or less.

"In the United Kingdom, 1.6 million individuals are on long-term levothyroxine regimens, most of whom have been prescribed it for primary hypothyroidism. If current practice continues, up to 30 percent of persons receiving levothyroxine therapy may have been prescribed it without an accepted indication and with the potential for net harm if they develop even a low thyrotropin level," the study concludes.


Story Source:

The above story is based on materials provided by American Medical Association (AMA). Note: Materials may be edited for content and length.


Journal Reference:

  1. Peter N. Taylor. Falling Threshold for Treatment of Borderline Elevated Thyrotropin Levels—Balancing Benefits and Risks. JAMA Internal Medicine, 2013; DOI: 10.1001/jamainternmed.2013.11312

Cite This Page:

American Medical Association (AMA). "Widespread prescribing of Levothyroxine for borderline thyroid hormone levels." ScienceDaily. ScienceDaily, 7 October 2013. <www.sciencedaily.com/releases/2013/10/131007162057.htm>.
American Medical Association (AMA). (2013, October 7). Widespread prescribing of Levothyroxine for borderline thyroid hormone levels. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2013/10/131007162057.htm
American Medical Association (AMA). "Widespread prescribing of Levothyroxine for borderline thyroid hormone levels." ScienceDaily. www.sciencedaily.com/releases/2013/10/131007162057.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) — Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) — The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) — Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) — New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins